Clinical trials
Metastatic Esophageal Squamous Cell Carcinoma clinical trials
Below are recruiting metastatic esophageal squamous cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 97 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06385730RecruitingPhase 2
PD-1 blocker before surgery for elderly esophageal cancer
This trial tests a drug (PD-1 blocker) given before surgery for people over 75 with esophageal cancer. The goal is to see if it helps shrink the tumor and improve outcomes.
Shanghai, Shanghai MunicipalityAges 76 years+ - NCT06444815RecruitingPhase 1
Study of VET3-TGI for advanced solid tumors
This trial tests an experimental treatment called VET3-TGI, which is injected directly into tumors. It is for people with advanced solid tumors who have already tried other treatments and are looking for new options.
Los Angeles, CaliforniaAges 18 years+ - NCT06596954Recruiting
Lymphocyte-sparing radiation for esophageal cancer
This trial tests a special type of radiation therapy that aims to spare your immune cells (lymphocytes) while treating esophageal cancer. It may help patients with locally advanced esophageal squamous cell carcinoma who are in good overall health.
Shanghai, ChinaAges 18–80 - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+ - NCT07403136RecruitingPhase 2
Testing Becotatug Vedotin ± Immunotherapy for advanced esophageal cancer
This trial tests a new targeted drug (Becotatug Vedotin) given either alone or with an immunotherapy drug for people with advanced esophageal squamous cell cancer that has EGFR protein on their tumor cells. The goal is to see if this combination can help when standard treatments have stopped working.
ShanghaiAges 18 years+ - NCT06780111RecruitingPhase 1/Phase 2
Combination therapy study for advanced esophageal cancer
This trial tests new drug combinations for people with advanced squamous cell cancer of the esophagus that hasn't been treated yet. It aims to see if these combinations can shrink tumors and help patients live longer.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06718205RecruitingPhase 2
Nimotuzumab plus immunotherapy and chemo for esophageal cancer
This study tests a new combination of drugs for advanced esophageal cancer. It adds an antibody (nimotuzumab) and an immunotherapy (sintilimab) to standard chemotherapy, aiming to improve how well treatment works.
Zhengzhou, HenanAges 18–75 - NCT06828588RecruitingEarly Phase 1
A new imaging test for people on HER2 cancer therapy
This study tests a new imaging drug called [68Ga]Ga-ABY-025 to see how well it shows HER2-positive tumors in people who are about to start or have just started HER2-targeted cancer therapy. It may help doctors see if the treatment is working.
Nashville, TennesseeAges 18 years+ - NCT07000253RecruitingPhase 2/Phase 3
Timing of local treatment for limited metastatic stomach or esophageal cancer
This trial tests whether giving local treatments (like surgery or radiation) to cancer spots later—after starting immunotherapy or targeted therapy—helps people with stomach or esophageal cancer that has spread to a few places. It aims to improve outcomes by timing treatments carefully.
AmsterdamAges 18 years+ - NCT07039162RecruitingPhase 2
Tislelizumab with chemo and radiation before surgery for advanced esophageal cancer
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation, followed by surgery, for people with advanced esophageal cancer that cannot be removed right away. It aims to see if this approach can help shrink the tumor enough to allow surgery.
Kaohsiung CityAges 20 years+ - NCT07050576Recruiting
Lymph node spread in early esophageal cancer
This trial looks at how early-stage esophageal cancer spreads to lymph nodes. It uses CT scans and pathology reports to understand patterns, which may help guide future treatment decisions.
Hefei, AnhuiAges Any age - NCT07061704RecruitingPhase 1/Phase 2
Oncolytic virus trial for esophageal cancer
This trial tests a virus-based therapy for locally advanced esophageal squamous cell carcinoma. It aims to see if the virus can target and kill cancer cells while sparing healthy tissue.
Chengdu, SichuanAges 18–80 - NCT07085091RecruitingPhase 1
Study of ALX2004 for advanced solid tumors
This trial tests a new drug, ALX2004, for people with certain advanced cancers (head and neck, lung, esophagus, or colorectal) that have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.
Tampa, FloridaAges 18 years+ - NCT07109726RecruitingPhase 1/Phase 2
Testing TER-2013 for advanced tumors with AKT/PI3K/PTEN changes
This trial tests a new drug called TER-2013, alone or combined with another drug (fulvestrant), for people with advanced solid tumors that have specific genetic changes in the AKT/PI3K/PTEN pathway. It aims to see if the drug is safe and effective.
Orlando, FloridaAges 18 years+ - NCT07188103RecruitingPhase 2
Ivonescimab and short radiation for advanced esophageal cancer
This trial combines a targeted immunotherapy drug (ivonescimab) with a short course of radiation to treat advanced esophageal cancer that has worsened after first treatment. It aims to see if this combination can help when standard options have stopped working.
Hefei, AnhuiAges 18–80 - NCT07189871RecruitingPhase 1/Phase 2
177Lu-BetaBart for advanced solid tumors
This trial tests a new radioactive drug, 177Lu-BetaBart, for people with certain advanced solid tumors that have stopped responding to other treatments. The goal is to see if it can shrink tumors or slow their growth.
Dothan, AlabamaAges 18 years+ - NCT07205731RecruitingPhase 2
Tislelizumab for older adults with advanced esophageal cancer
This trial tests a drug called tislelizumab (an immunotherapy) in older adults (70+) with advanced esophageal cancer who cannot have standard chemotherapy. The goal is to see if the drug can slow or shrink the cancer safely.
Annecy, Epagny Metz-TessyAges 70 years+ - NCT07284186RecruitingPhase 1
Study of PLX-61639 for advanced SMARCA4-mutant solid tumors
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
Scottsdale, ArizonaAges 18 years+ - NCT07290010RecruitingPhase 2
Iparomlimab plus chemotherapy for advanced esophageal cancer
This trial tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) with chemotherapy as a first treatment for advanced esophageal squamous cell carcinoma. It aims to see if this combination is safe and effective for people whose cancer cannot be removed by surgery or has spread.
Shijiazhuang, HebeiAges 18 years+ - NCT07339488RecruitingPhase 2
Low-dose radiation plus immunotherapy to shrink esophageal cancer before surgery
This trial tests whether a combination of low-dose radiation and immunotherapy can shrink advanced esophageal cancer enough to make it removable by surgery. It is for people whose cancer is considered borderline resectable or unresectable due to its location or spread.
Shantou, GuangdongAges 18–75 - NCT07359417RecruitingPhase 1
MR-guided radiation boost for esophageal cancer
This trial tests whether giving a higher dose of radiation to the main tumor, guided by MRI scans, can improve treatment for a type of esophageal cancer called squamous cell carcinoma. You would first receive standard chemoradiation followed by surgery.
Utrecht, UtrechtAges 18 years+ - NCT07390838RecruitingPhase 1
Study of SH009 for advanced solid tumors
This trial tests an investigational drug called SH009 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
ShanghaiAges 18 years+ - NCT07437898RecruitingPhase 2
Adebrelimab plus chemo before surgery for esophageal cancer
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy, given before surgery, helps shrink esophageal cancer tumors and improves outcomes. It is for people with a specific type of esophageal cancer that has not spread widely.
Putian, FujianAges 18–75 - NCT07457528RecruitingPhase 2
Chemo, radiation, and immune therapy before surgery for esophageal cancer
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (serplulimab and nimotuzumab) given before surgery for a certain type of esophageal cancer. It aims to see if this approach can safely improve outcomes.
Tianjin, Tianjin MunicipalityAges 18–75
Hear when a new Metastatic Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic esophageal squamous cell carcinoma?
- Yes. Clin2 currently lists 97 recruiting metastatic esophageal squamous cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic esophageal squamous cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic esophageal squamous cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Esophageal Squamous Cell Carcinoma
- Metastatic Clear Cell Renal Cell Carcinoma
- Metastatic Head and Neck Squamous Cell Carcinoma
- Advanced Esophageal Squamous Cell Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Locally Advanced Esophageal Squamous Cell Carcinoma
- Metastatic Oropharyngeal Squamous Cell Carcinoma
- Metastatic Hypopharyngeal Squamous Cell Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.